Dr. Ali Gholamrezanezhad is a fellow of the European Board on Nuclear Medicine (FEBNM), with research experiences at Johns Hopkins University and University Klinikum Bonn (Germany). He is also a Senior Investigator (Research Institute for Nuclear Medicine, Tehran University of Medical Sciences), Editorial Board Member of Rare Tumors, Anatolian Journal of Cardiology, Journal of Thoracic Disease, Eastern Journal of Medicine and Reviewer of Clinical Neurology and Neurosurgery, Iranian Journal of Nuclear Medicine, Anatolian Journal of Cardiology, Plasma Chemistry and Plasma Processing, etc. Dr. Gholamrezanezhad has published 84 peer reviewed papers with experiences on stem cell imaging, such as: In vivo tracking of 111In-Oxine labeled mesenchymal stem cells following infusion in Patients with advanced cirrhosis. Nuclear Medicine and Biology. Letter to the Editor: Emerging Approaches for Cardiovascular Stem Cell Imaging. Current Cardiovascular Imaging Reports. Cytotoxicity of 111In-Oxine on Mesenchymal Stem Cells: A Time Dependent Adverse Effect. Nuclear Medicine Communications. Is there any benefit in generating thyrocyte from stem cell? Polish Journal of Endocrinology. The first experience of stem cell labeling in Iran using 111In-Oxine. Iranian J Nucl Med.